The Hill: America’s medicine cabinet runs through Beijing
pharmaceutical sector — from research to manufacturing to global distribution. As Beijing inches closer to ultimately controlling the pipelines … these lower standards is a growing incentive for global pharmaceutical companies to shift early-stage development overseas, hollowing